Optimizing Treatments for Heart Failure During Hospitalization

NCT05910437 | Completed

• 1 other identifier: 2022PI115
• Study Type: observational
• Target: 184
• Locations: 1 country
• Sites: 2

Brief Summary

Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year. Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2). Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality. The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Conditions

Decompensated Heart Failure

Keywords

Decompensated heart failure

Outcome Measures

Primary Outcomes (1)

• Prescription score

  Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2.

  During hospitalisation for decompensated heart failure (up to 10 days)

Secondary Outcomes (5)

• serum concentration of creatinine

  During hospitalisation for decompensated heart failure (up to10 days)

• serum concentration of potassium

  During hospitalisation for decompensated heart failure (up to 10 days)

• Concentration of hemoglobin

  During hospitalisation for decompensated heart failure (up to 10 days)

• All cause Death

  6 months

• Rate of hospitalization for heart failure

  6 months

Interventions

Hospitalized patient for decompensated heart failure OTHER

Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hospitalized (≥24h) patient for decompensated heart failure in cardiology between november 2021 and october 2022

You may qualify if:

• Patient ≥ 18 years
• Hospitalized (≥24h) for decompensated heart failure in cardiology.

You may not qualify if:

• Patient opposition participation in research and use of data.

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (2)

Chr Metz Thionville

Ars-Laquenexy, 57530, France

Location

CHRU de NANCY

Vandœuvre-lès-Nancy, 54500, France

Location

Study Officials

• Nicolas GIRERD, MD-PhD

  CHRU de NANCY

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: coordinating investigator

Study Record Dates

• First Submitted: April 28, 2023
• First Posted: June 18, 2023
• Study Start: August 8, 2023
• Primary Completion: November 29, 2023
• Study Completion: November 29, 2023
• Last Updated: February 13, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (2)